非布司他治疗恶性肿瘤合并高尿酸血症的短期临床疗效分析

Analysis of Short-Term Clinical Efficacy of Febuxostat in the Treatment of Malignant Tumor Complicated with Hyperuricemia

摘要: 目的：观察非布司他治疗恶性肿瘤合并高尿酸血症患者的短期临床疗效。方法：回顾性分析2016年1月至2020年12月于青岛大学附属医院收治的新诊断或复发难治的恶性肿瘤合并高尿酸血症患者的临床资料，经排除后纳入138例有效患者，其中使用非布司他者62例(非布司他组)，使用别嘌醇者76例(别嘌醇组)。采用倾向性评分匹配以均衡组间协变量，比较两组患者用药1周后血尿酸、血肌酐、eGFR水平及不良反应发生情况。结果：经倾向性评分匹配后，两组各纳入40例患者，两组患者用药1周后的sUA、sCr水平均低于本组治疗前，差异有统计学意义(P < 0.05)。其中非布司他组sUA下降幅度大于别嘌呤醇组，而别嘌呤醇组sCr下降幅度大于非布司他组，两组比较差异均无统计学意义(P > 0.05)。治疗期间，非布司他组不良反应发生率为7.5%，别嘌醇组不良反应发生率为15%，差异无统计学意义(P > 0.05)。结论：非布司他治疗恶性肿瘤合并高尿酸血症患者的疗效及安全性与别嘌醇相似。

Abstract: Objective: To explore the short-term clinical efficacy of febuxostat in the treatment of malignant tumor patients with hyperuricemia. Methods: The clinical data of newly diagnosed or relapsed malignant tumor complicated with hyperuricemia admitted to the Affiliated Hospital of Qingdao University from January 2016 to December 2020 were retrospectively analyzed. After exclusion, 138 effective patients were included, including 62 patients who used febuxostat and 76 patients who used allopurinol. The tendency score matching was used to balance covariates between groups, and the levels of serum uric acid, serum creatinine, eGFR and the incidence of adverse reactions were compared between the two groups after 1 week of medication. Results: After PSM, 40 patients were included in each group. The levels of sUA and sCr in the two groups after 1 week of medication were lower than those before treatment, and the difference was statistically significant (P < 0.05). Among them, the decrease of sUA in febuxostat group was greater than that in allopurinol group, while the decrease of sCr in allopurinol group was greater than that in febuxostat group, and there was no significant difference between the two groups (P > 0.05). During treatment, the incidence of adverse reactions in febuxostat group was 7.5%, while that in allopurinol group was 15%, with no significant difference. Conclusion: The efficacy and safety of febuxostat in the treatment of malignant tumor with hyperuricemia are similar to those of allopurinol.